[Form 4] Incyte Genomics Inc Insider Trading Activity

Rhea-AI Filing Summary

On 26 June 2025, Incyte Corporation (NASDAQ: INCY) filed a Form 4 reporting an insider transaction by Chief Executive Officer and Director William Meury. The filing discloses a grant of 110,630 employee stock options with an exercise price of $70.81 per share. The options vest 25 % after one year, with the remaining 75 % vesting in equal monthly installments over the subsequent three years, and expire on 25 June 2035. After this grant, Meury beneficially owns 110,630 derivative securities, held directly. No purchases or sales of common stock were reported, and the transaction is classified as "A" (acquisition). The document was signed on 30 June 2025.

Insights

Portfolio Manager

TL;DR: Routine option grant; aligns CEO incentives, but limited immediate share-count impact—neutral for valuation.

This filing represents a standard executive compensation award rather than an open-market purchase or sale. The grant size (110,630 options) is modest relative to Incyte’s ~225 million shares outstanding and therefore does not meaningfully dilute shareholders. The $70.81 strike price appears set near prevailing market levels, indicating the award’s value depends on future performance. Because no common shares changed hands, near-term supply–demand dynamics remain unaffected. Overall, the disclosure is non-market-moving and is best viewed as routine alignment of management interests with shareholders.

Corporate Governance Analyst

TL;DR: Standard Section 16 filing; option grant follows typical four-year vesting—no governance red flags detected.

The Form 4 demonstrates timely compliance with Section 16 reporting requirements. Vesting over 48 months (25 % cliff plus monthly vesting) follows common practice, encouraging long-term value creation. The single-signatory structure confirms individual responsibility, and no 10b5-1 plan was referenced. Absent any accompanying stock sales, the filing does not suggest insider pessimism. While transparency is positive, the event is inherently not impactful to corporate governance risk assessments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meury William

(Last) (First) (Middle)

1801 AUGUSTINE CUT-OFF

(Street)

WILMINGTON DE 19803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Executive Officer		President

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$70.81	06/26/2025		A		110,630		(1)	06/25/2035	Common Stock	110,630	$0	110,630	D

Explanation of Responses:

1. The June 26, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Remarks:

	/s/ Elizabeth Feeney, Attorney-In-Fact	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Incyte (INCY) report on 26 June 2025?

The company granted 110,630 employee stock options to CEO William Meury.

What is the exercise price of the newly granted INCY options?

The exercise price is $70.81 per share.

How do the options vest for Incyte CEO William Meury?

They vest 25 % after one year, with the remaining shares vesting monthly over the next three years.

When do the Incyte stock options granted to the CEO expire?

The options expire on 25 June 2035.

Did the Form 4 report any sale or purchase of Incyte common stock?

No. The filing only reports an option grant; no common shares were bought or sold.